Poster exhibition
Viral vectors and vaccines

Programm

• • Poster
  • P 280

  Immunogenicity of Two Modified Vaccinia virus Ankara (MVA)-based Candidate Vaccines encoding Lassa Virus Glycoprotein or Nucleoprotein in mice

  • Dr. Alina Tscherne (Munich / DE)

   Viral vectors and vaccines
• • Poster
  • P 281

  Novel vaccines and therapeutic antibodies for West Nile Virus harnessing plasmid-based Virus-Like Particles production

  • Dr. Federico Bertoglio (Brunswick / DE)

   Viral vectors and vaccines
• • Poster
  • P 282

  Novel influenza A defective interfering particles for use as antivirals and vaccines

  • Tanya Dogra (Magdeburg / DE)

   Viral vectors and vaccines
• • Poster
  • P 283

  Hamster Model of Severe COVID-19 Demonstrates Differential Efficacy of first Licensed Western Vaccines in the Absence of Immunopathogenesis

  • Dr. Aileen Ebenig (Langen / DE)

   Viral vectors and vaccines
• • Poster
  • P 284

  Immunogenicity of the monovalent Omicron XBB.1.5-adapted BNT162b2 COVID-19 Vaccine in People Living with HIV (PLWH)

  • Dr. Laura Thümmler (Essen / DE)

   Viral vectors and vaccines
• • Poster
  • P 285

  Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disorders

  • Xiaoyan Wang (Essen / DE)

   Viral vectors and vaccines
• • Poster
  • P 286

  Induction of neutralizing antibodies targeting SARS-CoV-2 RBDs and HIV-1 MPER epitopes using tANCHOR-based immunization

  • Prof. Dr. Norbert Bannert (Berlin / DE)

   Viral vectors and vaccines
• • Poster
  • P 287

  Development of an efficient vaccine against porcine reproductive and respiratory syndrome virus

  • Kristina Kissner (Greifswald - Insel Riems / DE)

   Viral vectors and vaccines
• • Poster
  • P 288

  Target cell-specific nanobody-engineered AAV vectors for in vivo gene therapy approaches for HIV cure

  • Dr. Martin V. Hamann (Hamburg / DE)

   Viral vectors and vaccines
• • Poster
  • P 289

  Computational design of epitope-scaffolds targeting pan-coronavirus neutralizing antibody lineages

  • Tom Uwe Schlegel (Leipzig / DE)

   Viral vectors and vaccines
• • Poster
  • P 290

  Development of novel filovirus vaccines with computational protein design

  • Roman Trommler (Leipzig / DE)

   Viral vectors and vaccines
• • Poster
  • P 291

  Effect of different adjuvants used in foot and mouth disease virus vaccine on antibody response of buffalo calves

  • Dr. Qaiser Akram (Narowal / PK)

   Viral vectors and vaccines
• • Poster
  • P 293

  Development of a bivalent vaccine against Nipah virus infection and Aujeszky"s disease in swine

  • Dr. Walter Fuchs (Greifswald - Insel Riems / DE)

   Viral vectors and vaccines
• • Poster
  • P 294

  Computational design of pre-fusion stabilized viral glycoproteins as general strategy for pandemic preparedness

  • Prof. Dr. Clara T. Schoeder (Leipzig / DE)

   Viral vectors and vaccines
• • Poster
  • P 295

  Development and Characterization of a Human Papillomavirus-Based Nanoparticle Carrier for Heterologous Vaccine Antigens

  • Yu Wang (Erlangen / DE)

   Viral vectors and vaccines
• • Poster
  • P 296

  Characterization of bNAbs isolated from chronically infected HCV patients

  • Frithjof Besa (Luebeck / DE)

   Viral vectors and vaccines
• • Poster
  • P 297

  Improved immune response towards HCMV due to NKG2D stimulation

  • Anna Rebecca Siemes (Bonn / DE)

   Viral vectors and vaccines
• • Poster
  • P 298

  Biochemical and biophysical characterization of human neutralizing antibodies targeting the human cytomegalovirus trimer gH/gL/gO in complex

  • Divya Amarambedu Selvakumar (Luebeck / DE)

   Viral vectors and vaccines
• • Poster
  • P 299

  An immunosuppressive region within the gamma retroviral surface envelope protein identified through in vitro and in vivo studies

  • Dr. Philip Podschwadt (Essen / DE)

   Viral vectors and vaccines
• • Poster
  • P 300

  Maximizing mucosal memory: Systemic prime-mucosal boost vaccination against SARS-CoV-2 induces durable mucosal B- and T-cell response

  • Vera Viherlehto (Erlangen / DE)

   Viral vectors and vaccines
• • Poster
  • P 301

  Molecular cloning and host range analysis of three cytomegaloviruses from Mastomys natalensis

  • Laura Staliunaite (Hamburg / DE)

   Viral vectors and vaccines
• • Poster
  • P 302

  High-resolution viromes of individual ticks revealed the highly diversed tick-borne viral communities in association with different tick species

  • Professor Fei Deng (Wuhan / CN)

   Viral vectors and vaccines
• • Poster
  • P 303

  A Varicella-Zoster virus variant based on the Oka vaccine strain with strongly reduced genome size

  • Michael Mannbar-Frahm (Kiel / DE)

   Viral vectors and vaccines
• • Poster
  • P 305

  Efficacy of emergency maternal MVA-ZIKV vaccination in a rapid challenge model of lethal Zika infection

  • Dr. Sabrina Clever (Hanover / DE)

   Viral vectors and vaccines
• • Poster
  • P 306

  Influence of the number of T helper cell epitopes of a VLP-vaccine on the magnitude of Intrastructural help

  • Dr. Enhao Zhou (Erlangen / DE)

   Viral vectors and vaccines
• • Poster
  • P 307

  Generation of a recMVA vaccine candidate targeting EVD68-VP1

  • Jan Seib (Hanover / DE)

   Viral vectors and vaccines
• • Poster
  • P 309

  Improved Immunogenicity and Protective Capacity of Single Dose Vaccination with Stabilized Recombinant MERS-CoV Spike Antigen

  • Dr. Sabrina Clever (Hanover / DE)

   Viral vectors and vaccines
• • Poster
  • P 310

  Rapid protective MVA-SARS-2-ST vaccination induces robust T cell responses against SARS-CoV-2 in Syrian hamsters

  • Christian Meyer zu Natrup (Hanover / DE)

   Viral vectors and vaccines
• • Poster
  • P 311

  Development of a therapeutic HPV16 vaccine based on the viral vector VSV-GP

  • Melanie Schmitt (Innsbruck / AT)

   Viral vectors and vaccines
• • Poster
  • P 312

  Assessing vaccine effectiveness of a RIG-I adjuvanted CMV mRNA vaccine in the murine model

  • Maeva Katzmarzyk (Brunswick / DE)

   Viral vectors and vaccines
• • Poster
  • P 313

  Development of broadly protective Outer Membrane Vesicle based intranasal betacoronavirus vaccine

  • Dr. Kaneemozhe Harichandran (Berlin / DE)

   Viral vectors and vaccines
• • Poster
  • P 314

  AAV-mediated expression of therapeutic antibodies via minimal invasive applicationAAV-mediated expression of therapeutic antibodies via minimal invasive application

  • Valentina Eberlein (Leipzig / DE)

   Viral vectors and vaccines
• • Poster
  • P 315

  Human saliva induces inactivation and exerts type-specific effects on adenovirus infectivity

  • Dr. Erwan Sallard (Witten / DE)
  • Professor Malik Aydin (Witten / DE)

   Viral vectors and vaccines
• • Poster
  • P 316

  Development of a third-generation lentiviral vector system for flow virometry

  • Paula Isabel Busskamp Castro (Essen / DE)

   Viral vectors and vaccines
• • Poster
  • P 317

  Neutralisation efficiency of SARS-CoV-2 lineages KP.3.1.1 and XEC following booster vaccination with the novel JN.1-adapted mRNA vaccine

  • Dr. Prerna Arora (Goettingen / DE)

   Viral vectors and vaccines
• • Poster
  • P 318

  Assessing the replication competence of MCMV-based vector vaccines in the Syrian Hamster model

  • Linlin Qiao (Brunswick / DE)

   Viral vectors and vaccines
• • Poster
  • P 319

  Unravelling host responses to Codon Pair Deoptimization in SARS-CoV-2

  • Christine Langner (Berlin / DE)

   Viral vectors and vaccines